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genomically well-characterized forms of cancer. Mutations in coding
genes that occur at frequencies greater than 5% above background are
likely to have already been identiﬁed (Lawrence et al., 2014), revealing
a landscape of potentially actionable drug targets. Growth factor recep-
tor ampliﬁcation and mutations, including epidermal growth factor re-
ceptor (EGFR) alterations, PIK3CA mutations and PTEN deletion and
mutation are especially common (Brennan et al., 2013). In all, growth
factor receptor signaling is activated by copy number alterations and
mutations in close to 90% of tumors sampled. To date, this information
has yet to translate into new treatments or better outcomes for patients.
Acting upon insights gained by the genomic road map will require a
deeper understanding of how speciﬁc mutations cause tumors through
reprogramming of signaling, metabolic, and epigenetic networks, par-
ticularly with regard to identifying therapeutic vulnerabilities
(Cloughesy et al., 2014). Tumormodels will play a central role in this ef-
fort. In this issue of EBioMedicine, Xie et al. provide an important, new,
shared resource that directly addresses this critical need (Yuan et al.,
2015).
Much of what we know about cancer, including GBM, has come
through studying established tumor cell lines in culture. Adherent can-
cer cell lines in serum-containing culture, which are widely shared by
the cancer research community, have been used to identify most of
the oncogenes and tumor suppressors that we know are important in
cancer. Further, studies in these established cell lines have yielded im-
portant insights into the behavior and function of tumor cells, including
some aspects of the molecular determinants of response to treatments.
The Cancer Cell Line Encyclopedia, a pioneering effort using such
established cell lines, illustrates this point (Barretina et al., 2012).
Transgenes, siRNAs, shRNAs, and CRISPR constructs can readily be intro-
duced into established cell lines, enabling exquisitely detailed gain and
loss of function studies in an isogenic background. These types of rela-
tively “reductionist” analyses in a simpliﬁed system remain exception-
ally valuable, particularly when they are coupled to correlational
studies in clinical samples, additional mechanistic studies in cell cultureDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.08.026.
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plex behavior of tumors in situ.
However, these established cell lines cultured in serum have a num-
ber of signiﬁcant limitations. They are less heterogeneous than the tu-
mors from which they are derived; they tend to lack the invasive
growth pattern characteristic of GBMs when implanted into the brain;
and some of the signature genetic alterations, including EGFR ampliﬁca-
tion and mutations such as EGFRvIII, are lost within a small number of
in vitro passages. Thismay relate to the potential link between focal am-
pliﬁcation of growth factor receptors in GBM and extrachromosomal
DNA (Nathanson et al., 2014; Nikolaev et al., 2014), although this pro-
cess is, as yet, incompletely understood. Serum-containing cultures
also disfavor the putative glioma stem cell (GSC) subpopulation,
which appears to play a potentially key role in the genesis, proliferation
and drug resistance of GBM(Lathia et al., 2015). GSC lines have been de-
veloped and used extensively for studies in vitro and in vivo, but the rel-
ative shortage of GSC lines that are shared by the ﬁeld, and the relative
lack of high-resolutionmolecular and clinical data associatedwith these
lines and the tumors from which they were derived, has limited their
usefulness. A set of patient derived cell culture models that addresses
these key concerns is needed.
Xie et al. have established a library of 48 patient derived cultures ob-
tained from surgical resections of a representative set of patients. These
cell lines, which aremaintained in standard serum-free stem cell culture
conditions, have been extensively characterized at the molecular level,
revealing the mutations and DNA copy number variations that are
present in the parent tumor and are characteristic of GBM in general.
Transcriptional proﬁling of these lines, particularly with regard to the
four main transcriptional subclasses (classical, mesenchymal, neural,
and proneural), similarly reveals transcriptional programs that are
shared with the tumor of origin and characteristic of GBMs in general.
These cell lines also exhibit a GSC-like phenotype and form tumors in
the brains of mice that recapitulate the histologic and molecular fea-
tures of the GBMs from which they were derived.
Most importantly, the authors have taken their work a step further
by committing to make this cell library, and the associated molecular
and clinical data, an open resource that is fully available to the commu-
nity through a supported online database. As such, the cell line models
described in this manuscript substantially augment the current toolbox
of patient derived xenograft models and existing GSC lines (Sarkariathe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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to the patients.
The cancer research community is awash in data — genomic,
transcriptomic, epigenomic, proteomic, and metabolic. The models
have lagged behind. What are the “right”model systems? In what con-
text should they be used? What are the strengths and limitations of
such model systems? How can they be used as a resource for the ﬁeld
so that molecular insights can be reproducibly translated into new
treatments and better outcomes for patients? The cancer research com-
munity is still ﬁguring this out. Getting it right may be one of the key
steps towards more effective translation of genomic insights into better
therapies. Xie et al. have provided an important patient-derived, GSC-
based cell line resource that augments the existing toolkit of established
GBM cell lines, patient-derived xenografts and mouse genetic models.
Each of these model systems has an important and proper place in the
collective effort to turn scientiﬁc insight into more effective therapies
for patients.
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